LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer. Patent No. 1,204,683, entitled “Ovarian cancer cells and myeloma cell surface glycoproteins, antibodies thereto, and uses therof,” covers aspects of the Company’s monoclonal antibody ICT-69, which targets human multiple myeloma and ovarian cancer cells. ICT-69 is already covered in the United States and this patent expands coverage of Company’s issued patent portfolio to nine.
